ATE539761T1 - Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion - Google Patents

Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion

Info

Publication number: ATE539761T1
Authority: AT; Austria
Prior art keywords: agent; injection; solution; wap; composition
Prior art date: 2006-06-29

Application number

AT07767796T

Other languages

English (en)

Inventor

Hirofumi Nakajima

Haruhiko Machida

Original Assignee

Arigen Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-29

Filing date

2007-06-28

Publication date

2012-01-15

2007-06-28 Application filed by Arigen Pharmaceuticals Inc filed Critical Arigen Pharmaceuticals Inc

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE539761T1 publication Critical patent/ATE539761T1/de

Links

238000002347 injection Methods 0.000 title abstract 3
239000007924 injection Substances 0.000 title abstract 3
239000000243 solution Substances 0.000 title abstract 3
230000003115 biocidal effect Effects 0.000 title abstract 2
239000003795 chemical substances by application Substances 0.000 title 2
239000003242 anti bacterial agent Substances 0.000 title 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
239000000203 mixture Substances 0.000 abstract 3
229920000858 Cyclodextrin Polymers 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 2
108010002156 Depsipeptides Proteins 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
239000008121 dextrose Substances 0.000 abstract 1
239000003085 diluting agent Substances 0.000 abstract 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
238000001802 infusion Methods 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
229910000403 monosodium phosphate Inorganic materials 0.000 abstract 1
235000019799 monosodium phosphate Nutrition 0.000 abstract 1
239000003002 pH adjusting agent Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 abstract 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT07767796T 2006-06-29 2007-06-28 Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion ATE539761T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2006179778		2006-06-29
PCT/JP2007/063003 WO2008001849A1 (en)	2006-06-29	2007-06-28	Agent for injection purposes comprising antibiotic, and solution for injection comprising the agent

Publications (1)

Publication Number	Publication Date
ATE539761T1 true ATE539761T1 (de)	2012-01-15

Family

ID=38845613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07767796T ATE539761T1 (de)	2006-06-29	2007-06-28	Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion

Country Status (17)

Country	Link
US (1)	US7968588B2 (de)
EP (1)	EP2047857B1 (de)
JP (1)	JP5272126B2 (de)
KR (1)	KR101286038B1 (de)
CN (1)	CN101578103B (de)
AT (1)	ATE539761T1 (de)
AU (1)	AU2007266063B2 (de)
BR (1)	BRPI0713080A2 (de)
CA (1)	CA2656604C (de)
DK (1)	DK2047857T3 (de)
ES (1)	ES2378279T3 (de)
MX (1)	MX2009000155A (de)
PL (1)	PL2047857T3 (de)
PT (1)	PT2047857E (de)
RU (1)	RU2462261C2 (de)
SI (1)	SI2047857T1 (de)
WO (1)	WO2008001849A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101931880A (zh)	2009-06-19	2010-12-29	中兴通讯股份有限公司	一种多媒体广播组播业务动态复用的资源分配方法
JP5878302B2 (ja) *	2010-05-25	2016-03-08	株式会社ゲノム創薬研究所	新規環状ペプチド化合物とその製造方法及び感染症治療薬
JP5878303B2 (ja) *	2010-05-25	2016-03-08	株式会社ゲノム創薬研究所	抗生物質含有画分、その抗生物質及びその抗生物質の製造方法
MY200159A (en) *	2016-12-14	2023-12-09	Sk Biopharmaceuticals Co Ltd	Parenteral liquid preparation comprising carbamate compound
US10975121B2 (en)	2017-06-24	2021-04-13	Cytogel Pharma, Llc	Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
CN111683654A (zh) *	2017-11-30	2020-09-18	细胞凝胶制药有限责任公司	新型镇痛药物制剂及其用途
KR102434276B1 (ko)	2017-12-08	2022-08-18	엘지디스플레이 주식회사	표시장치
US12343374B2 (en)	2018-06-13	2025-07-01	Kyoto Biopharmaceuticals, Inc.	Enhancement of antibacterial actions of a depsipeptide antibiotic using synergistic amounts of boric acid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3339235B2 (ja) *	1994-02-18	2002-10-28	日本メディカルリサーチ株式会社	抗生物質ｗａｐ−８２９４ａ、その製造法及び抗菌剤
KR100225601B1 (ko) *	1995-02-02	1999-10-15	오쿠다 기요아키	항생물질 wap-8294a와 이의 제조방법 및 항균조성물
JP4270588B2 (ja) *	1996-11-14	2009-06-03	康武日地	神経毒軽減麻酔剤
KR19980033113A (ko)	1996-10-25	1998-07-25	야스다케 히지	국소 마취제 수용액, 국소 마취제의 용해도를 개선시키는 방법, 신경독성이 감소된 국소 마취제 및 국소 마취제의 신경 독성을 감소시키는 방법
US6869927B1 (en) *	1997-12-22	2005-03-22	Human Genome Sciences, Inc.	Keratinocyte growth factor-2 formulations
WO2000062793A2 (en)	1999-04-15	2000-10-26	Eli Lilly And Company	Pseudomycin antifungal compositions and methods for their use
AU5593200A (en) *	1999-06-02	2000-12-18	Human Genome Sciences, Inc.	Keratinocyte growth factor-2 formulations
JP4074457B2 (ja) *	2001-12-20	2008-04-09	田辺三菱製薬株式会社	ヘパリン溶液入りプレフィルドシリンジ製剤およびその製造方法
EP1487540A2 (de) *	2002-03-20	2004-12-22	Pharmacia Corporation	Lagerfähige eplerenon-formulierung
AUPS188302A0 (en) *	2002-04-22	2002-05-30	Fujisawa Pharmaceutical Co., Ltd.	Pharmaceutical composition
JP2003321364A (ja) *	2002-05-07	2003-11-11	Eisai Co Ltd	シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
WO2003094889A1 (fr) *	2002-05-13	2003-11-20	Daiichi Pharmaceutical Co., Ltd.	Produit de lyophilisation
DE10228049A1 (de) *	2002-06-24	2004-01-15	Merck Patent Gmbh	Flüssige Zubereitung enthaltend Oligopeptide
US7361683B2 (en) *	2004-11-24	2008-04-22	Yung Shin Pharm. Ind., Co., Ltd	Paclitaxel aqueous injection solution and methods for preparing the same

2007
- 2007-06-28 RU RU2009102803/15A patent/RU2462261C2/ru not_active IP Right Cessation
- 2007-06-28 US US12/306,663 patent/US7968588B2/en not_active Expired - Fee Related
- 2007-06-28 DK DK07767796.1T patent/DK2047857T3/da active
- 2007-06-28 CN CN2007800322662A patent/CN101578103B/zh not_active Expired - Fee Related
- 2007-06-28 SI SI200730847T patent/SI2047857T1/sl unknown
- 2007-06-28 PT PT07767796T patent/PT2047857E/pt unknown
- 2007-06-28 KR KR1020097001274A patent/KR101286038B1/ko not_active Expired - Fee Related
- 2007-06-28 WO PCT/JP2007/063003 patent/WO2008001849A1/ja not_active Ceased
- 2007-06-28 CA CA2656604A patent/CA2656604C/en not_active Expired - Fee Related
- 2007-06-28 PL PL07767796T patent/PL2047857T3/pl unknown
- 2007-06-28 MX MX2009000155A patent/MX2009000155A/es active IP Right Grant
- 2007-06-28 JP JP2008522624A patent/JP5272126B2/ja not_active Expired - Fee Related
- 2007-06-28 AT AT07767796T patent/ATE539761T1/de active
- 2007-06-28 EP EP07767796A patent/EP2047857B1/de not_active Not-in-force
- 2007-06-28 BR BRPI0713080-5A patent/BRPI0713080A2/pt not_active Application Discontinuation
- 2007-06-28 ES ES07767796T patent/ES2378279T3/es active Active
- 2007-06-28 AU AU2007266063A patent/AU2007266063B2/en not_active Ceased

Also Published As

Publication number	Publication date
EP2047857A4 (de)	2010-05-26
AU2007266063B2 (en)	2011-09-08
DK2047857T3 (da)	2012-02-27
RU2462261C2 (ru)	2012-09-27
BRPI0713080A2 (pt)	2012-10-09
SI2047857T1 (sl)	2012-03-30
ES2378279T3 (es)	2012-04-10
CN101578103A (zh)	2009-11-11
KR101286038B1 (ko)	2013-07-19
US20090258920A1 (en)	2009-10-15
RU2009102803A (ru)	2010-08-10
MX2009000155A (es)	2009-03-25
CA2656604A1 (en)	2008-01-03
AU2007266063A1 (en)	2008-01-03
PL2047857T3 (pl)	2012-05-31
JP5272126B2 (ja)	2013-08-28
US7968588B2 (en)	2011-06-28
CN101578103B (zh)	2013-09-25
PT2047857E (pt)	2012-03-15
CA2656604C (en)	2014-01-07
EP2047857A1 (de)	2009-04-15
KR20090030317A (ko)	2009-03-24
JPWO2008001849A1 (ja)	2009-11-26
EP2047857B1 (de)	2012-01-04
WO2008001849A1 (en)	2008-01-03

Similar Documents

Publication	Publication Date	Title
US11872266B2 (en)	2024-01-16	Rapid-acting insulin compositions
SI2047857T1 (sl)	2012-03-30	Sredstvo za injiciranje ki vsebuje antibiotik in raztopina za injiciranje ki vsebuje to sredstvo
EA200700389A1 (ru)	2007-08-31	Стабильный при хранении инфузионный раствор дигидроптеридинонов
SI2640358T1 (en)	2018-05-31	Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
EA201200490A1 (ru)	2012-12-28	Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения
IL291556B1 (en)	2023-10-01	Methods and compositions for administration of arylsulfatase A to the central nervous system
MX2010004169A (es)	2010-10-05	Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
ATE430564T1 (de)	2009-05-15	Stabile pharmazeutische zusammensetzungen aus antitumoralen platin-(ii)-mitteln
KR970702033A (ko)	1997-05-13	택산 계열 유도체-기본 약학 조성물(taxane class derivative based pharmaceutical compositions)
DE60116483D1 (de)	2006-03-30	Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
BRPI0418474A (pt)	2007-06-19	solução aquosa parenteral estável
MX2020014262A (es)	2021-03-25	Composicion farmaceutica que comprende un agente basico poco soluble.
BRPI0415001A (pt)	2006-11-07	droga contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo
DE502004002585D1 (de)	2007-02-15	Flüssige zubereitung enthaltend tobramycin
CL2008001332A1 (es)	2009-01-02	Uso de temozolomida para preparar un medicamento util para el tratamiento de un desorden proliferativo.
WO2007056263A3 (en)	2007-11-08	Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
CA2496121A1 (en)	2004-02-26	Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy
UA93365C2 (ru)	2011-02-10	Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
ITMI20052515A1 (it)	2007-06-30	Formulazione farmaceutica per il trattamento della osteoartrite
NO20061458L (no)	2006-07-03	Infusjonspreparat inneholdende (2R)-2-propyloktansyre som den aktive bestanddel
TWI410250B (zh)	2013-10-01	以榖胱甘肽作為氫氧化四甲基銨之解毒劑
UA84578C2 (ru)	2008-11-10	Лекарственное средство, содержащее (2r)-2-пропилоктановую кислоту в качестве активного ингредиента
NZ770000A (en)	2024-08-30	Aqueous formulation comprising 1-(4-{ [4-(dimethylamino)piperidin-1-yl]carbonyl} phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
PT1683518E (pt)	2009-07-20	Formulação farmacêutica de formoterol e propilenoglicol
NZ747321B2 (en)	2025-09-18	Phosphaplatin liquid formulations